Reszon Diagnostics INTERNATIONAL

Why Missed Detection of Strongyloidiasis is Dangerous?



Mortality rate of hyperinfection syndrome and disseminated strongyloidiasis can reach almost 90% if left untreated

STRONGYLOIDIASIS IS OFTEN ASYMPTOMATIC BUT POTENTIALLY FATAL.

Strongyloidiasis is a chronic human parasitic infection mainly caused by *Strongyloides stercoralis*, a soil-transmitted helminth (STH) capable of persisting in the human host for decades through a unique autoinfection cycle. This ability allows larvae to reinvade the host without external re-exposure, making strongyloidiasis fundamentally different from other STH infections and a major reason it often remains undetected for years.

The content of this material is intended for Healthcare Professionals only, not for general public.

WHY MISSED DETECTION OF STRONGYLOIDIASIS IS DANGEROUS?

In at-risk patients, strongyloidiasis can rapidly progress to:



HYPERINFECTION SYNDROME

Massive increase of larvae in the gastrointestinal (GI) tract and lungs



DISSEMINATED INFECTION

Larvae invade to multiple organs (liver, central nervous system, heart, skin, etc.)

LEFT UNTREATED, THE MORTALITY RATES OF HYPERINFECTION SYNDROME AND DISSEMINATED STRONGYLOIDIASIS CAN APPROACH 90%.

WHO ARE AT HIGHER RISK OF SEVERE DISEASE (HYPERINFECTION/DISSEMINATED STRONGYLOIDIASIS)?

1 IMMUNOSUPPRESSED INDIVIDUALS

- Patients infected with human immunodeficiency virus (HIV) or human T-lymphotropic virus type 1 (HTLV-1)
- Patients receiving chemotherapy for cancer
- Solid organ transplant recipients
- Hematopoietic stem cell (bone marrow) transplant recipients
- Advanced chronic kidney disease (CKD)
- Patients with autoimmune or inflammatory diseases receiving immunosuppressive drugs (e.g. rheumatoid arthritis)
- Patients with severe malnutrition or other causes of impaired cellular immunity

2 PATIENTS RECEIVING CORTICOSTEROID THERAPY

Both short-term and long-term systemic corticosteroid therapy can increase the risk of *Strongyloides* hyperinfection syndrome

3 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES



Leukemia



Lymphoma and other haematological malignancies

The content of this material is intended for Healthcare Professionals only, not for general public.

WHY PROACTIVE SCREENING OF STRONGYLOIDIASIS MATTERS

1 STRONGYLOIDIASIS IS PREVENTABLE AND TREATABLE

Although *Strongyloides stercoralis* infection may persist silently for decades, it is preventable and treatable.

Effective Treatment Available
Ivermectin **has been shown to be safe and effective in clearing infection and reducing parasite burden.**

Prevention of Hyperinfection in Asymptomatic Carriers
Screen at-risk individuals before initiating immunosuppressive therapy, especially corticosteroids, and treat seropositive individuals.

Clinical Insight
Asymptomatic strongyloidiasis is common, but once detected and treated, progression to severe forms can be prevented.

2 SCREENING BEFORE IMMUNOSUPPRESSION CAN BE LIFESAVING

Patients receiving immunosuppressive therapy, especially corticosteroids or biologics, are at risk of progression from latent strongyloidiasis to hyperinfection syndrome or disseminated disease, which is often fatal if unrecognized.

Corticosteroid
Corticosteroids suppress the immune response that control autoinfection, allowing unchecked larval proliferation.

Guideline support
Several expert reviews recommend screening for strongyloidiasis in all patients scheduled for immunosuppressive therapy, especially in endemic regions or in those with epidemiological risk factors.

Clinical Insight
Identifying and treating chronic strongyloidiasis before initiating immunosuppression effectively prevents hyperinfection syndrome and disseminated strongyloidiasis.



3 EARLY DETECTION PREVENTS DEVASTATING COMPLICATIONS AND DEATH

When chronic strongyloidiasis remains undetected before immunosuppression, hyperinfection syndrome or disseminated strongyloidiasis may develop, leading to potential life-threatening complications such as sepsis, respiratory failure, meningitis, and multiorgan failure. These complications are associated with high mortality rates, even with treatment.

High mortality
Mortality among patients with hyperinfection syndrome, particularly when complicated by bacterial sepsis, can exceed 60–85%. Disseminated strongyloidiasis carries an even higher mortality, reaching up to 87%.

Complication reduction through screening
Early detection enables pre-emptive treatment to clear infection before immunosuppression, markedly reducing the likelihood of severe sequelae.

Clinical Insight
Delayed diagnosis is associated with systemic bacterial sepsis and multi-organ dysfunction, underscoring why early detection is vital.

The content of this material is intended for Healthcare Professionals only, not for general public.

DON'T WAIT FOR SYMPTOMS: EARLY SCREENING FOR STRONGYLOIDIASIS SAVES LIVE

Strongyloidiasis is a silent threat with potentially devastating consequences when overlooked. What often begins as an asymptomatic, chronic infection can rapidly become a life-threatening medical emergency once the host becomes immunosuppressed.

With mortality rates approaching 90% in severe cases, missed diagnosis is more than a diagnostic failure—it may result in preventable mortality. Proactive screening, timely diagnosis, and effective treatment offer a powerful opportunity to interrupt this trajectory. By identifying and treating strongyloidiasis early, especially before immunosuppression, clinicians can prevent hyperinfection, avoid catastrophic complications, and ultimately save lives.

Early detection of Strongyloidiasis
is not optional; it is lifesaving.

CONTACT US

For more information, feel free to reach out to our team!

WhatsApp	:	**+6012 815 8689**
Phone	:	**+603 8022 1162**
Email	:	**info@reszonics.com**
Website	:	**www.reszonics.com**

Contact Now

References:

1. Osman E, Noordin R, Mohd R, Kamaruzaman L, Abdul Manap SNA, Mohd. Zali S I, Azhar NA, Anuar NS. (2025) *Strongyloides seroprevalence in patients with advanced chronic kidney disease at a tertiary hospital in Malaysia: Epidemiological profiles and comparison of two assays*. *Parasite Epidemiol Control*. 2025, 31: e00458.
2. Rahumatullah A, Samsudin N, Mohamed Z, Noordin R, Abdullah ADG, Baharudeen Z, Bakar MQA, Anuar NS, Zakaria NZ, Hussain Ahmad H. (2025) *Molecular and Serological Diagnosis of Strongyloides stercoralis Infection Among Cancer Patients at Hospital Universiti Sains Malaysia*. Trop Biomed. 2025 Dec 1;42(4):422-429. doi: 10.47665/tb.42.4.008. PMID: 41619242.
3. CDC - DPDx (2019) *Strongyloidiasis* [Accessed 27 Apr 2026]
4. WHO (n.d.) *Strongyloidiasis Key Facts* [Access 27 Apr 2026]
5. Keiser PB, Nutman TB. *Strongyloides stercoralis in the Immunocompromised Population*. Clin Microbiol Rev. 2004 Jan;17(1):208-17. doi: 10.1128/CMR.17.1.208-217.2004. PMID: 14726461; PMCID: PMC321465.
6. Schär F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al. (2013) *Strongyloides stercoralis*: Global Distribution and Risk Factors. PLoS Negl Trop Dis 7(7): e2288. *https://doi.org/10.1371/journal.pntd.0002288*

ABOUT RESZON DIAGNOSTICS

Established since October 11th, 2010, Reszon Diagnostics International Sdn. Bhd. (Reszon), a member of Hextar Healthcare Berhad develops and manufactures a strong portfolio of innovative in-vitro diagnostics (IVD) rapid tests for medical professionals, including clinical diagnostic markets worldwide.

Reszon's IVD rapid test kits enable medical professionals to diagnose diseases quickly and accurately for the early detection and prevention of diseases. The simple assay procedures plus portability of its rapid test kits make them ideal for applications in a wide range of settings, including remote areas and countries where sophisticated medical diagnostics are not available. Reszon is actively transforming its manufacturing process to full automation in order to competitively address growing global needs. Reszon is also committed to providing the best affordable diagnostics in the self-testing sector.

At Reszon, we continue to create solutions for healthcare institutions, laboratories, medical offices from all around the world. The test results derived from our testing device play a critical role in point-of-care decision making, influencing majority of critical healthcare decisions for millions of people worldwide.

Intended use of the products mentioned vary. For specific intended use statements, please refer to instruction for use from manufacturer.

© 2026 Reszon Diagnostics International Sdn. Bhd. All rights reserved. All trademarks are the property of Reszon Diagnostics International Sdn. Bhd. unless otherwise specified.